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ABSTRACT
Introduction: Ovarian cancer (OC) is associated with
non-specific symptoms such as bloating, making
accurate diagnosis challenging: only 1 in 3 women
with OC presents through primary care referral.
National Institute for Health and Care Excellence
guidelines recommends sequential testing with CA125
and routine ultrasound in primary care. However, these
diagnostic tests have limited sensitivity or specificity.
Improving accurate triage in women with vague
symptoms is likely to improve mortality by
streamlining referral and care pathways. The Refining
Ovarian Cancer Test Accuracy Scores (ROCkeTS; HTA
13/13/01) project will derive and validate new
tests/risk prediction models that estimate the
probability of having OC in women with symptoms.
This protocol refers to the prospective study only
(phase III).
Methods and analysis: ROCkeTS comprises four
parallel phases. The full ROCkeTS protocol can be found
at http://www.birmingham.ac.uk/ROCKETS. Phase III is
a prospective test accuracy study. The study will recruit
2450 patients from 15 UK sites. Recruited patients
complete symptom and anxiety questionnaires, donate a
serum sample and undergo ultrasound scored as per
International Ovarian Tumour Analysis (IOTA) criteria.
Recruitment is at rapid access clinics, emergency
departments and elective clinics. Models to be evaluated
include those based on ultrasound derived by the IOTA
group and novel models derived from analysis of
existing data sets. Estimates of sensitivity, specificity,
c-statistic (area under receiver operating curve),
positive predictive value and negative predictive value
of diagnostic tests are evaluated and a calibration plot
for models will be presented. ROCkeTS has received
ethical approval from the NHS West Midlands REC
(14/WM/1241) and is registered on the controlled
trials website (ISRCTN17160843) and the National
Institute of Health Research Cancer and Reproductive
Health portfolios.
INTRODUCTION
Ovarian cancer (OC) is the seventh most
common cancer in women worldwide, with
239 000 new cases diagnosed in 2012.1 In the
UK, OC has an annual incidence of 7116
women and causes 4271 deaths; the lifetime
risk of developing OC is 1 in 54.2 Seventy per
cent of patients will present at an advanced
stage (stages III/IV). The International Cancer
Benchmarking Project showed that the reason
that OC survival in the UK is signiﬁcantly
lower than other western countries seems to
be related to a lower proportion of patients
receiving treatment and surviving the ﬁrst year
after cancer diagnosis and is likely due to a
delay in diagnosis.3 Five-year survival rates are
43% overall but over 90% for early-stage
Strengths and limitations of this study
▪ ROCkeTS conforms to the PROBE design for
biomarker evaluation and STARD criteria for test
accuracy studies.
▪ Stringent efforts to collect outcome data to
prevent ascertainment bias.
▪ Inbuilt ultrasound quality control.
▪ Recruitment is at secondary care, so the popula-
tion will be less heterogeneous than that is seen
in primary care.
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tumours.4 High-grade serous is the most common histo-
type (80%). Worryingly, long-term survival from OC has
remained static over the past decades at 30%.2
OC was previously considered a ‘silent killer’; it is now
recognised that patients with OC suffer from a number
of non-speciﬁc symptoms. These include abdominal
bloating, distension, feeling full quickly and/or loss of
appetite, pelvic/abdominal pain, increased urinary
urgency and/or frequency, unexplained weight loss,
fatigue or changes in bowel habit. These symptoms are
very common.5 6 Interrogation of UK General Practice
databases suggest that on average one in two women
between the ages of 45 and 74 presents once a year to
her general practitioner (GP)/primary care doctor with
these symptoms. Abdominal bloating alone5 6 is docu-
mented in 16–30% of women presenting to GPs.7
Diagnostic challenges are considerable given (1) the low
incidence of OC (a GP sees a woman with OC once in
3–5 years) and (2) the low positive predictive value
(PPV) of symptoms (only 1 in 400–600 symptomatic
women have OC).8 9 Unfortunately, these diagnostic
challenges result in nearly 36% of women, subsequently
diagnosed with OC, presenting to the GP with symptoms
three or more times prior to diagnosis.10 Two large pro-
spective studies of symptom-triggered testing for OC
suggest that symptom-triggered testing using CA125 is
likely to result in referral of a higher proportion of
patients with resectable disease.11 12
The UK introduced symptom-triggered testing for OC
in women with vague symptoms in 2011. National
Institute for Health and Care Excellence (NICE) guide-
lines recommend sequential testing using serum CA125
followed by pelvic ultrasound scan (USS) in women
(particularly aged ≥50) presenting to primary care with
symptoms such as persistent abdominal distension/
‘bloating’, feeling full and/or loss of appetite, pelvic/
abdominal pain, increased urinary urgency and/or fre-
quency, unexplained weight loss, fatigue or changes in
bowel habit on a persistent or frequent basis.13 However,
the NICE guidelines do not specify the type of ultra-
sound abnormalities that should prompt referral.
Current tests have limited sensitivity with CA125 being
elevated only in 40–50% of women with stage 1 OC in
screening and presurgical studies.14 15 Once referred to
secondary care, women with complex masses considered
benign can undergo laparoscopic or conservative
management, whereas women with malignancy who
undergo surgery by trained gynaecological oncologists
have the best outcome.16 17 Use of NICE guidelines in
practice is extremely variable. A survey of 258 GPs
reported that the majority would refer patients on the
basis of raised CA125 even if the USS was normal.18 A
recent audit revealed that the majority of referrals
(90%) for suspected OC did not follow the guidelines.
Referrals were heterogeneous with regard to which
symptoms prompted these, what GPs considered to be
abnormal CA125 level or abnormal USS.19 Two-thirds of
women referred were premenopausal.19
Therefore, improved diagnostic tools in primary care
and better presurgical triage in secondary care are likely
to improve mortality in patients with OC. Optimal diag-
nostic pathways for premenopausal women with sus-
pected OC/complex ovarian mass and raised CA125
also need to be deﬁned. Ovarian cysts in premenopausal
women are extremely common; however, it is important
to recognise that about 1000 women under 50 will be
diagnosed with OC in the UK annually.2
The National Institute of Health Research Health
Technology Assessment programme commissioned
ROCkeTS—‘Reﬁning Ovarian Cancer Test accuracy
Scores’ 13/13/01 (1 October 2014 and 30 September
2018)—which aims to identify, reﬁne and validate tests
and clinical risk scores (risk prediction models) that esti-
mate the probability of having OC in postmenopausal
and premenopausal women with symptoms, in primary
and secondary care. The project comprises four phases/
work packages: phase I—systematic reviews of existing
risk prediction algorithms and biomarkers to detect OC;
phase II—interrogation of data sets from two large OC
trials: the screening trial UKCTOCS and the preopera-
tive detection International Ovarian Tumour Analysis
(IOTA) studies to derive or reﬁne risk scores with bio-
markers from the systematic review; phase III—a pro-
spective study to validate new scores in women newly
referred to secondary care with symptoms of OC and
phase IV—a model of the diagnostic pathway across
primary and secondary care. A cost consequence analysis
of testing pathways will be delivered as part of ROCkeTS.
The full ROCkeTS protocol can be found at http://
www.birmingham.ac.uk/ROCKETS.
The ROCkeTS project evaluates risk prediction models
derived from conventional tests—symptoms, ultrasound
variables and commercially available serum blood tests.
Phase III of ROCkeTS is a cross-sectional study aimed
at establishing the accuracy of tests and prediction
models for the diagnosis of prevalent OC. However, of
necessity, the reference standard for a correct diagnosis
is follow-up to 12 months, as the study is not restricted to
women scheduled for immediate surgery. This is a diag-
nostic trial (not a screening trial) as women are symp-
tomatic and referred to secondary care.
The phase III prospective study will recruit 2450 pre-
menopausal and postmenopausal symptomatic women
over 23 months (recruitment started in June 2015).
Patients will be recruited through rapid access clinics,
emergency departments or through routine clinic refer-
rals, reﬂecting the heterogeneity of diagnostic routes for
OC in the UK.
Recruited patients consent to complete a validated
symptom questionnaire, donate a serum sample and
undergo an USS scored as per the IOTA criteria.
Standard care pathways are followed beyond this point.
Patients are triaged to receive surgery or conservative
management based on standard of care model risk of
malignancy index (RMI) scores for postmenopausal
women, using a threshold of 250 in postmenopausal
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women or as per local unit practice in premenopausal
women. This threshold was selected by the funder as
comparator as part of the commissioning brief as this is
current standard of care in the UK.13 Participants and
treating doctors will be blinded to the new biochemical
serum test results which will be performed in batches as
these are not part of standard clinical care. Outcome
data will be collected from histology reports in women
undergoing surgery or biopsy and from follow-up over
12 months of those managed conservatively. Symptom
scores, serum biomarker tests and ultrasound data will
be analysed at the end of follow-up to validate risk pre-
diction models derived in phases I and II.
ROCKETS STUDY DESIGN
Aim of the study
▸ To derive and validate risk prediction models that
estimate the probability of having OC for women with
symptoms suggestive of OC for postmenopausal and
premenopausal women.
▸ To identify optimal risk thresholds of best models
for the diagnosis of OC that can guide patient
management.
Design
The ROCkeTS study is a single-arm prospective cohort
diagnostic test accuracy study to evaluate existing and
novel risk prediction models for premenopausal and
postmenopausal women with symptoms.
A test accuracy study is different from an effectiveness
study in that randomisation of participants is not
involved. It is designed to generate a comparison of
measurements obtained by tests under investigation
(index tests) with those obtained from current standard
of care tests (comparator test) against a reference stand-
ard. In this way, the accuracy of any new ‘index’ tests can
be estimated. A reference standard is a test that conﬁrms
or refutes the presence or absence of disease beyond
reasonable doubt. Therefore, it is sometimes also known
as the ‘gold standard’. In this study, as per standards of
diagnostic test evaluation, estimates of sensitivity, speciﬁ-
city, c-statistic (area under receiver operating curve
(ROC) curve), PPV and negative predictive value (NPV)
of tests evaluated and a calibration plot for models evalu-
ated will be presented.
Here, the reference standard will be histology of
tissues taken from patients who proceed to surgery or
biopsy or follow-up using structured templates at a
minimum of 12 months after presentation. The accuracy
of the index test will be compared against that of the
comparator test, the existing standard risk prediction
score RMI. This index is an algorithm combining meno-
pausal status, CA125 and ultrasound features and is
standard of care in the UK.20 In ROCkeTS, the index
test (novel risk prediction models) will be derived in
phases I and II and validated in phase III. We will iden-
tify biochemical markers, symptom indices and USS as
likely components of a novel risk prediction model, as
these may be implemented across primary and second-
ary care. Therefore, we will collect symptom question-
naires, blood and USS data in the study to be analysed
and validated at the end of the study.
POSSIBLE COMPONENTS OF THE NEW RISK PREDICTION
MODEL(S)
Symptoms
Case–control studies demonstrate that symptom ques-
tionnaires have good diagnostic accuracy; however, they
need to be reﬁned for use by patients in primary
care21 22 as the duration of symptoms preceding diagno-
sis is uncertain.22 Symptom questionnaires may help
triage patients prior to referral and would help standard-
ise symptoms for any prediction model. This is particu-
larly important, given the subjective nature of eliciting
symptoms through unstructured clinical history taking
and the existing audit evidence that they are interpreted
variably by GPs who will only see few cases of OC in
their practice. A robust symptom score that can triage
referral based on a questionnaire may be very useful.
Biochemical markers
A number of serum biomarker tests (multiplex testing—
OVA1) and multiple-marker-based algorithms (Risk of
Ovarian Malignancy Algorithm, ROMA) have been iden-
tiﬁed in the past decade. Abnormal Human Epididymis
4 (HE4) biomarker levels may improve risk stratiﬁcation
for OC. A recent systematic review reports that HE4 may
improve the diagnostic performance of CA125; however,
studies showed considerable heterogeneity.23
Ultrasound-based models—IOTA risk prediction models
After publication of an agreement on terms, deﬁnitions
and measurement methods to describe adnexal
masses,24 the IOTA collaboration set out multicentre
studies on large cohorts of patients presenting with an
adnexal mass. The IOTA database has enabled previ-
ously developed prediction models to be tested and
novel prediction models and rules to characterise
ovarian pathology prior to surgery to be developed and
validated.25 26 In a systematic review with meta-analysis,
IOTA algorithms such as the simple rules were identiﬁed
to be the best presurgical diagnostic tools to characterise
adnexal masses, with improved performance over the
RMI.27 Although the Royal college of Obstetricians and
Gynaecologists (RCOG) included the simple rules in
their guidance for evaluating ovarian pathology in preme-
nopausal women, IOTA models are not commonly used
in National Health Service (NHS) clinical practice.28
Recently, the ADNEX (Assessment of Different
NEoplasias in the adneXa) model was published. As a
multiclass prediction model, it differs from all other
models by differentiating between malignant and benign
masses and also discriminating between four types of
malignant tumours (borderline ovarian tumours, stage I
Sundar S, et al. BMJ Open 2016;6:e010333. doi:10.1136/bmjopen-2015-010333 3
Open Access
 o
n
 24 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2015-010333 on 9 August 2016. Downloaded from 
OC, stages II–IV OC and metastatic tumours of other
primary origin). ADNEX still needs an extensive external
validation but is considered to be promising.29
Target population
1. Postmenopausal and premenopausal women with
symptoms of suspected OC. Symptoms are as deﬁned
by NICE guidelines, including but not restricted to
persistent or frequent abdominal distension, feeling
full (early satiety) and/or loss of appetite, pelvic or
abdominal pain, increased urinary urgency and/or
frequency and postmenopausal bleeding. Symptoms
listed here are not an exhaustive list, and this will be
updated from any symptoms identiﬁed through
phase I systematic reviews of literature.
2. Patients referred with symptoms from GP as sus-
pected OC.
Comparator
RMI cut-off of 250.30
Source of potential participants
The potential participants are patients who are referred
to secondary care as outpatients, either as urgent 2-week
or routine referrals, USS clinics, inpatient or emergency
presentation.
Inclusion and exclusion criteria
Multicentre trials across the UK which meet the eligibil-
ity criteria are described below.
Inclusion criteria
▸ Newly presenting premenopausal and postmenopausal
women with symptoms of suspected OC and either
raised CA125, abnormal USS or both. Menopause is
deﬁned as >12 months of amenorrhoea.
▸ Patients aged between 16 and 90 years.
▸ Patients able to provide informed consent.
NB—Patients with >120 days delay between initial regis-
tration IOTA scan and surgery will need a repeat IOTA
scan prior to surgery.
Exclusion criteria
▸ USS reveals non-ovarian pathology, for example,
ﬁbroids.
▸ Patients who decline transvaginal scan.
▸ Previous ovarian malignancy.
▸ Pregnant patients.
▸ Patients with previous bilateral oophorectomy.
▸ Active non-ovarian malignancy—women with a
medical history of cancer are eligible only if there are
no documented persistent or recurrent diseases and
have not received treatment for this in the last
12 months. This exclusion does not apply to patients
with premalignant disease, for example, cervical
intraepithelial neoplasia or patients receiving tamoxi-
fen/other drugs to prevent breast cancer recurrence.
See ﬁgure 1 for participant ﬂow through the trial.
STUDY PROCEDURES AND TESTS
The index tests
There are three index tests that will be performed in the
prospective single-arm test accuracy study.
1. Participants entering the study will complete a
symptom elicitation questionnaire and anxiety ques-
tionnaire (STA6) and impact of event score.
2. Ultrasonographers will record the USS variables and
score the USS using IOTA simple rules and ADNEX
models.29 31 32 For most women in the trial, this will
only mean some additional data being collected
during their USS appointment. For a small number
of women, this may mean an additional USS after
consent.
3. Participants will have an additional blood sample
taken at baseline for biomarker assessment at the
end of the study. Serum will be banked for testing at
a later point. Treating doctors will be blinded to any
new biomarker assessments performed as part of this
trial. Details of blood sample collection will be pro-
vided in a laboratory manual.
Apart from the study tests, all other aspects of partici-
pant management are entirely at the discretion of the
local doctors and as per the RCOG guidelines for the
management of these participants.28 30 Treating clini-
cians will be asked to record their treatment recommen-
dations as per standard care and after any additional
USS information to assess the impact of this test on care
pathways.
Quality assurance of index tests
The performance of USS is subjective and operator
dependent. Therefore, sonographers/doctors carrying
out USS will undergo a face-to-face IOTA training course
provided as part of their participation in the ROCkeTS
trial. Sites will commit to undergoing quality assurance
during the ROCkeTS trial. Online USS training materi-
als will be developed during this project for future use
by the UK NHS. Quality assurance of testing will begin
with a clearly documented staff training programme.
A register of staff who have been trained and had their
competence assessed will be maintained, and only staff
whose names appear on this list will be permitted to
undertake scans within the ROCkeTS prospective trial.
Staff will also receive a site visit and assessment of their
competence. Competence will be assessed by those
authorised by the IOTA team.
Reference standard/follow-up schedule
Reference standard for the study will be histology of
tissue taken at surgery or biopsy in women who are
managed surgically following study enrolment. Histology
data collected will include information on whether the
tumour was considered invasive cancer or borderline.
The outcome of participants referred for suspected OC
who do not undergo surgery will be assessed by a
follow-up visit at 12 months, by a telephone call or a ques-
tionnaire from the research nurse at 12 months, as per
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the local investigators’ discretion and clinical assessment.
Well-being will be ascertained at this follow-up. A struc-
tured template will be used. Women will also be asked to
give permission for data to be linked with cross-checked
against national cancer registry data so that we are able to
identify the false-negative rate for any diagnostic tests.
Sample size
The diagnostic accuracy from models will be compared to
the current tests recommended by NICE for primary and
secondary care. The sample size has a 90% power to
detect with 5% signiﬁcance difference in accuracy
between the existing test (RMI threshold 250) and the
new model. Owing to the expected difference in perform-
ance in premenopausal and postmenopausal women, sep-
arate sample sizes have been calculated. Sample sizes are
calculated assuming independence of test errors and
interim analyses will conﬁrm parameter assumptions.
For postmenopausal women
The performance of RMI at threshold 250 is assumed
to be 70% sensitive and 90% speciﬁc.30 One thousand
and four hundred participants will be required to
detect an increase in sensitivity of 10% (to 80%) and
in speciﬁcity of 5% (to 95%). Based on a prevalence of
30% of OC in referred women (local audit ﬁgures),
with sensitivity and speciﬁcity of RMI assumed to be
70% and 90%, a sample size of 1333 provides 90%
power to detect an increase of sensitivity to 80% and
speciﬁcity to 95% in paired data (conservatively assum-
ing independence of test errors). Allowing for a loss
to follow-up of up to 5%, this gives a ﬁnal sample size
of 1400.
For premenopausal women
The performance of RMI is assumed to have a sensitivity
of 72% and a speciﬁcity of 46% (local audit ﬁgures).
The trial is powered to detect an increase in sensitivity
of 10% (to 82%) and in speciﬁcity of 10% (to 56%).
Prevalence of OC in premenopausal women referred to
secondary care is about 10%.19 A sample size of 1000
will provide 100 OC events in which to build new
models combining symptom and test data (adequate
events to model 10 predictor variables) and will provide
Figure 1 Flow chart. GP, general practitioner; IOTA, International Ovarian Tumour Analysis; RCOG, Royal College of
Obstetricians and Gynaecologists; RMI, risk of malignancy index.
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90% power to detect an increase in speciﬁcity of 8%
(from 46% for RMI to 54%). With a predicted loss to
follow-up of up to 5%, the ﬁnal sample size required is
1050 women.
Study duration
We anticipate recruitment of 2450 participants within
23 months, with a minimum of 12 months follow-up
from the last participant entering the study.
Data collection
All information will be collected on standard proformas
(case report forms; CRF) and identiﬁed by study
number. Information will be collated on paper forms
and then either copied and sent to the coordinating
centre for input or entered directly into the study data-
base via a web interface. A data set including age, ethni-
city, parity, GP details and signiﬁcant medical/surgical
history will be collected. We aim to use the NHS
number as the primary identiﬁer when linking to
national registries and to track individuals throughout
the NHS. Additional data on outcomes such as cancer
or non-cancereous conditions will be collected at
follow-up.
Data will be collected on relevant medical, obstetric
and gynaecological, surgical history, emotional impact as
well as information on the symptoms that prompted GP
referral or investigation. USS information will be col-
lected. Data on the reference diagnosis will be obtained
from the histopathology report and a structured tem-
plate to assess well-being for participants who do not
undergo surgery will be collected directly from the parti-
cipants. Importantly, outcomes collected will include all
conditions/diagnoses in women with non-speciﬁc
symptoms.
Measures and costs
Validation of a risk prediction model and tests for esti-
mating the probability of OC in women with suspected
OC, key outcome measures include the accuracy of the
tests and models in terms of their discrimination ability
(eg, sensitivity, speciﬁcity) and calibration (observed vs
predicted probabilities), and the identiﬁcation of thresh-
olds to guide patient management decisions.
Trial data collection will be undertaken prospectively
for all participants in order to inform the costs for each
pathway.
Analysis plan—test accuracy
We will report estimates of sensitivity, speciﬁcity, c-statistic
(area under ROC curve), PPV and NPV of tests
evaluated and a calibration plot for models evaluated.
Also, in terms of our new model derived from phase II
of the wider ROCkeTS project, its improvement over
existing models will be summarised by comparing the
c-statistic and the calibration. We will also summarise the
net-reclassiﬁcation index for each new predictor that
existing models omitted.
The risk prediction models derived in phases I and II
of the ROCkeTS project will each produce a predicted
risk of OC by 12 months for all the individuals in our
study. Therefore, we will compare the observed outcome
at 12 months with this predicted risk. The calibration (in
terms of calibration slope) and discrimination (eg,
c-statistic) will be evaluated for the models derived and
identiﬁed in phase I and phase II, and their perform-
ance will be compared to the existing RMI model. The
calibration will be shown visually by grouping women
into deciles ordered by predicted risk and considering
the agreement between the mean predicted risk and
the observed events in each decile. The aim was to use
predeﬁned models on the phase III data, so the bulk of
phase III analysis will be external validation of prede-
ﬁned models. Where the data set is used to derive a new
model, optimism will be reduced using shrinkage
methods through internal validation.
Generalisability of results to primary care
We appreciate that there may be recalibration required
for any models validated within ROCkeTS in the
primary care setting. However, we stress that to conduct
a study that recruited women in primary care to validate
diagnostic models would need to be extremely large and
prohibitively expensive. Furthermore, our work and
others have shown that GPs are likely to refer on the
basis of a raised CA125 or abnormal scan rather than
follow the NICE suggested referral pathway which is
based on sequential CA125 and USS and referral only if
both are abnormal.18 19 Thus, we believe that the popu-
lation of patients referred through rapid access clinics
with symptoms will be more heterogeneous than antici-
pated from the NICE guidelines and therefore maybe
more applicable to a primary care population.
Analysis plan—cost consequence analysis
Resource usage for each of the diagnostic tests will be
broken down and displayed along with their unit costs
alongside the outcomes for each pathway. The resource
usage will include the types of tests administered, the
number of inpatient and outpatient consultations, and
any operative procedures undertaken. This approach
will help to show which are the major cost drivers for
each of the diagnostic pathways and will be collected as
part of the clinical CRF.
Study conduct
The conduct of the study will be in accordance with the
Research Governance Framework for Health and Social
Care and/or the Research Governance Framework for
Health and Community Care. The participant’s written
informed consent to participate in the trial will be
obtained before any trial procedures or questionnaires
are completed. The women’s GP will be notiﬁed of her
participation in the study with her consent (GP letter).
Participants will be free to withdraw from the study at
any time without any effect on their standard of care;
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data and samples provided up to the point a participant
withdraws will be retained unless the participant
expressly requests their removal. This is because analysis
will be based on all recruited participants and per
protocol.
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